文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Immunotherapy and tumor microenvironment.

作者信息

Tang Haidong, Qiao Jian, Fu Yang-Xin

机构信息

Department of Pathology and Committee on Immunology, University of Chicago, Chicago, IL 60637, USA.

Department of Pathology and Committee on Immunology, University of Chicago, Chicago, IL 60637, USA.

出版信息

Cancer Lett. 2016 Jan 1;370(1):85-90. doi: 10.1016/j.canlet.2015.10.009. Epub 2015 Oct 19.


DOI:10.1016/j.canlet.2015.10.009
PMID:26477683
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4725050/
Abstract

Recent exciting progress in cancer immunotherapy has ushered in a new era of cancer treatment. Immunotherapy can elicit unprecedented durable responses in advanced cancer patients that are much greater than conventional chemotherapy. However, such responses only occur in a relatively small fraction of patients. A positive response to immunotherapy usually relies on dynamic interactions between tumor cells and immunomodulators inside the tumor microenvironment (TME). Depending on the context of these interactions, the TME may play important roles to either dampen or enhance immune responses. Understanding the interactions between immunotherapy and the TME is not only critical to dissect the mechanisms of action but also important to provide new approaches in improving the efficiency of current immunotherapies. In this review, we will highlight recent work on how the TME can influence the efficacy of immunotherapy as well as how manipulating the TME can improve current immunotherapy regimens in some cases.

摘要

相似文献

[1]
Immunotherapy and tumor microenvironment.

Cancer Lett. 2016-1-1

[2]
Targeting the tumor microenvironment and T cell metabolism for effective cancer immunotherapy.

Eur J Immunol. 2019-7-9

[3]
Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade.

Front Immunol. 2021

[4]
PD-L1 blockade restores CAR T cell activity through IFN-γ-regulation of CD163+ M2 macrophages.

J Immunother Cancer. 2022-6

[5]
CCL21 Programs Immune Activity in Tumor Microenvironment.

Adv Exp Med Biol. 2020

[6]
Translational Biomarkers and Rationale Strategies to Overcome Resistance to Immune Checkpoint Inhibitors in Solid Tumors.

Cancer Treat Res. 2020

[7]
Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors.

Int Immunopharmacol. 2018-7-2

[8]
FcγR-Binding Is an Important Functional Attribute for Immune Checkpoint Antibodies in Cancer Immunotherapy.

Front Immunol. 2019-2-26

[9]
A Threshold Model for T-Cell Activation in the Era of Checkpoint Blockade Immunotherapy.

Front Immunol. 2019-3-18

[10]
The next generation of immunotherapy: keeping lung cancer in check.

J Hematol Oncol. 2017-4-24

引用本文的文献

[1]
Neutrophil Dynamics in Response to Cancer Therapies.

Cancers (Basel). 2025-8-7

[2]
Durvalumab and tremelimumab plus local partial tumour ablation (radiofrequency ablation or stereotactic radiotherapy) in patients with unresectable liver metastases from metastatic colorectal cancer: results of the EORTC-1560-GITCG multicentre, single-arm phase II study (ILOC).

ESMO Open. 2025-7-23

[3]
Myeloperoxidase expressing tumor associated neutrophils are associated with worse prognosis in metastatic breast cancer patients.

Sci Rep. 2025-7-12

[4]
Global research trends in liver regeneration and immunomodulation: A perspective from bibliometric analysis.

Hum Vaccin Immunother. 2025-12

[5]
G0S2: a potential target for NSCLC identified through prognostic models from multi-Omic analysis of regulatory T cell metabolic genes.

NPJ Precis Oncol. 2025-6-19

[6]
Real-world analysis of immunochemotherapy in recurrent small-cell lung cancer: opportunities for second-line approaches.

Front Pharmacol. 2025-5-30

[7]
Helicobacter pylori is associated with less tumor-infiltrating lymphocytes and a poor prognosis in gastric cancer.

BMC Gastroenterol. 2025-5-30

[8]
Harnessing the power of tumor-draining lymph nodes: unveiling predictive biomarkers for immune checkpoint inhibitor.

Explor Target Antitumor Ther. 2025-5-13

[9]
Animal models in preclinical metastatic breast cancer immunotherapy research: A systematic review and meta-analysis of efficacy outcomes.

PLoS One. 2025-5-7

[10]
Exploring the Role of Cellular Interactions in the Colorectal Cancer Microenvironment.

J Immunol Res. 2025-4-11

本文引用的文献

[1]
Engineering CAR-T cells: Design concepts.

Trends Immunol. 2015-8

[2]
Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy.

Nat Immunol. 2015-6-15

[3]
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.

N Engl J Med. 2015-5-21

[4]
Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes.

Nat Med. 2015-5

[5]
Innate immune recognition of cancer.

Annu Rev Immunol. 2015-1-22

[6]
The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?

Curr Opin Immunol. 2015-1-23

[7]
Immune checkpoint combinations from mouse to man.

Cancer Immunol Immunother. 2015-7

[8]
Microenvironmental regulation of therapeutic response in cancer.

Trends Cell Biol. 2015-4

[9]
STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors.

Immunity. 2014-11-20

[10]
STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors.

Immunity. 2014-11-20

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索